Lars-Uwe Scholtz (Bielefeld), Christoph Pfeiffer (Bielefeld), Alexander Kilgué (Bielefeld), Conrad Riemann (Bielefeld), Philipp Kühnel (Bielefeld), Matthias Schürmann (Bielefeld), Ingo Todt (Bielefeld)
Objectives:
Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) suffer from a variety of symptoms such as loss of smell, mucus flow from the nose and otologic symptoms such as chronic tube dysfunction.
Methods:
The retrospective study included 18 adult patients fulfilling the criteria for the indication of biologic therapy for chronic rhinosinusitis with nasal polyps and suffering from chronic tube dysfunction. We analyzed the sino-nasal outcome test-22 (SNOT-22), sniffing tests, EDTQ-7, tone threshold audiogram, CT scans, nasal polyp score (NPS), tubomanometry (TMM) and tympanometry.
preResults:
All patients received treatment with dupilumab (IL 4, IL 13). There was a significant improvement in the SNOT -22 score. The nasal polyp score (NPS) and the ability to smell were significantly improved. The EDTQ-7 score was significantly reduced. The TMM results show a tendency towards improvement.
Conclusion:
The biologics prescribed for CRSwNP are associated with a significant reduction in chronic Eustachian tube dysfunction. Studies comparing the therapeutic effect of tube dilation with biologic therapy in patients with chronic rhinosinusitis with nasal polyps are needed.
nein
We use cookies on our website. Cookies are small (text) files that are created and stored on your device (e.g., smartphone, notebook, tablet, PC). Some of these cookies are technically necessary to operate the website, other cookies are used to extend the functionality of the website or for marketing purposes. Apart from the technically necessary cookies, you are free to allow or not allow cookies when visiting our website.